Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

Merck’s push to make Keytruda injectable has triggered a patent dispute with Halozyme. The conflict arises over the use of ...

Merck posted strong Q4 earnings, with a 7% revenue increase to $15.62 billion, beating expectations. Growth was driven by ...

Merck's newly developed injected version of its blockbuster cancer drug, Keytruda, may be at the center of a potential patent ...

The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.

Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

For some years industry observers have been asking what Merck & Co can do to reduce its reliance on blockbuster cancer immunotherapy Keytruda. Now, it seems a key part of that effort will come ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other ...

Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

Stocks to Consider. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other Dobermans of the Dow to buy. The Dobermans of the Dow strategy serves as an ...

Merck & Co is enjoying blockbuster revenues as its cancer immunotherapy Keytruda is becoming standard of care in a range of cancers. But some of those revenues are helping British scientists ...